236 related articles for article (PubMed ID: 30704697)
21. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis.
Wang J; Nie B; Xiong W; Xu Y
J Clin Pharm Ther; 2012 Apr; 37(2):204-11. PubMed ID: 21740451
[TBL] [Abstract][Full Text] [Related]
22. Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment Paradigm.
Wilkie M; Finch S; Schembri S
COPD; 2015; 12(5):582-90. PubMed ID: 25774769
[TBL] [Abstract][Full Text] [Related]
23. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
Hizawa N
Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
[TBL] [Abstract][Full Text] [Related]
24. The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).
Albertson TE; Chenoweth JA; Pearson SJ; Murin S
Expert Opin Pharmacother; 2020 Feb; 21(2):213-231. PubMed ID: 31955671
[No Abstract] [Full Text] [Related]
25. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
Decramer M; Dahl R; Kornmann O; Korn S; Lawrence D; McBryan D
Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
[TBL] [Abstract][Full Text] [Related]
26. Adherence to long-acting inhaled therapies among patients with chronic obstructive pulmonary disease (COPD).
Cecere LM; Slatore CG; Uman JE; Evans LE; Udris EM; Bryson CL; Au DH
COPD; 2012 Jun; 9(3):251-8. PubMed ID: 22497533
[TBL] [Abstract][Full Text] [Related]
27. [Medical treatment of COPD].
Vestbo J; Titlestad IL
Ugeskr Laeger; 2013 Apr; 175(18):1261-4. PubMed ID: 23651802
[TBL] [Abstract][Full Text] [Related]
28. Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender.
Tashkin DP; Varghese ST
Pulm Pharmacol Ther; 2011 Feb; 24(1):147-52. PubMed ID: 20659577
[TBL] [Abstract][Full Text] [Related]
29. Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
Wedzicha JA; Buhl R; Lawrence D; Young D
Respir Med; 2015 Jan; 109(1):105-11. PubMed ID: 25433954
[TBL] [Abstract][Full Text] [Related]
30. Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: A nationwide cohort study 2002-2013.
Cho KH; Kim YS; Linton JA; Nam CM; Choi Y; Park EC
Respir Med; 2017 Sep; 130():75-84. PubMed ID: 29206637
[TBL] [Abstract][Full Text] [Related]
31. Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history.
Bateman ED; Rabe KF; Calverley PM; Goehring UM; Brose M; Bredenbröker D; Fabbri LM
Eur Respir J; 2011 Sep; 38(3):553-60. PubMed ID: 21737553
[TBL] [Abstract][Full Text] [Related]
32. Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD).
Chalmers JD; Poole C; Webster S; Tebboth A; Dickinson S; Gayle A
Respir Res; 2018 Apr; 19(1):63. PubMed ID: 29642882
[TBL] [Abstract][Full Text] [Related]
33. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.
Hanania NA
Pulm Pharmacol Ther; 2008; 21(3):540-50. PubMed ID: 18280761
[TBL] [Abstract][Full Text] [Related]
34. Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.
Calverley PM; Eriksson G; Jenkins CR; Anzueto AR; Make BJ; Persson A; Fagerås M; Postma DS
Int J Chron Obstruct Pulmon Dis; 2017; 12():13-25. PubMed ID: 28031707
[TBL] [Abstract][Full Text] [Related]
35. Intensified Therapy with Inhaled Corticosteroids and Long-Acting β
Stolz D; Hirsch HH; Schilter D; Louis R; Rakic J; Boeck L; Papakonstantinou E; Schindler C; Grize L; Tamm M
Am J Respir Crit Care Med; 2018 May; 197(9):1136-1146. PubMed ID: 29266965
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment.
Pelaia G; Muzzio CC; Vatrella A; Maselli R; Magnoni MS; Rizzi A
Expert Opin Pharmacother; 2015; 16(13):2009-21. PubMed ID: 26194120
[TBL] [Abstract][Full Text] [Related]
37. An evaluation of early medication use for COPD: a population-based cohort study.
Falk J; Dik N; Bugden S
Int J Chron Obstruct Pulmon Dis; 2016; 11():3101-3108. PubMed ID: 27994449
[TBL] [Abstract][Full Text] [Related]
38. Physical activity in COPD patients decreases short-acting bronchodilator use and the number of exacerbations.
Katajisto M; Koskela J; Lindqvist A; Kilpeläinen M; Laitinen T
Respir Med; 2015 Oct; 109(10):1320-5. PubMed ID: 26298024
[TBL] [Abstract][Full Text] [Related]
39. Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial.
Cosío BG; Shafiek H; Iglesias A; Yanez A; Córdova R; Palou A; Rodriguez-Roisin R; Peces-Barba G; Pascual S; Gea J; Sibila O; Barnes PJ; Agusti A
Chest; 2016 Jul; 150(1):123-30. PubMed ID: 27107490
[TBL] [Abstract][Full Text] [Related]
40. Inhaled corticosteroids in COPD: friend or foe?
Agusti A; Fabbri LM; Singh D; Vestbo J; Celli B; Franssen FME; Rabe KF; Papi A
Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30190269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
